Top of this page
Skip navigation, go straight to the content

Our Products Products Vimpat® - Epilepsy

Vimpat®

 
image description
 

Europe

In the European Union, Vimpat® (lacosamide) (film-coated tablets, syrup and solution for infusion) is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Vimpat® solution for infusion may be used when oral administration is temporarily not feasible.

 

USA

In the US, Vimpat®  (lacosamide) CV is indicated

  • for the treatment of partial-onset seizures in patients 4 years of age and older
  • as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

In the U.S., Vimpat® is available as oral tablets, oral solution and injection.

 

Other countries

For availability of Vimpat® in other countries, please consult our local websites.